VEGFA and non-small cell lung carcinoma: Furthermore, combining erlotinib and bevacizumab in patients with NSCLC who had not received prior anti-VEGF or anti-EGFR treatment, showed response rates (CR/PR) of 18-20% [31, 32] and improved progression-free survival (PFS), but not overall survival (OS) [33].